EIKCS 2022: Novel combination therapy shows promise in advanced kidney cancer
A combination therapy with a new targeted therapy (tyrosine kinase [...]
Genetic biomarkers for the survival of kidney cancer patients
Previously, researchers found some genes that helped identify which patients [...]
Nivolumab plus ipilimumab and live bacteria supplements in advanced kidney cancer
Researchers are interested in the bacteria in our gut (the [...]
Ipilimumab plus nivolumab combination approved for use on the NHS
The National Institute for Health and Care Excellence (NICE) has [...]
Patient-reported outcomes with nivolumab plus cabozantinib in advanced kidney cancer
Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib have been [...]
First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients
A recent study published in Journal of Clinical Medicine this [...]
SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of [...]
ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
